MiniMed 780G system performance in older users with type 1 diabetes: Real‐world evidence and the case for stricter glycaemic targets
Main finding · Mean TIR, all usersResult — go to the resultΔ 4.0 95% CI 3.8–4.2Authors' conclusion
This real-world analysis demonstrated that older MiniMed™ 780G system users with type 1 diabetes can achieve a TIR >70% without increasing hypoglycaemia risk. Users employing optimal settings showed the best outcomes. The system performed as well as or better than in younger users. These findings support the case that more stringent TIR targets can be achieved safely.
Study context
- Population
- MiniMed 780G advanced hybrid closed-loop system users with T1D
- Participants
- 7,415 vs 35,366
- Exposure
- MiniMed 780G users aged ≥56 years vs aged 16-55 years
- ≥56 yearsn = 7,415
- 16-55 yearsn = 35,366reference
- Outcome
- TIR 70-180 mg/dL
Methodological detailsmultinational
- Multinational
Main finding
Mean TIR, all users
Δ
4.0
95% CI 3.8–4.2
P < 0.0001
By group
≥56 yearsvs 16-55 years
Δ 4.0 (95% CI 3.8–4.2); P < 0.0001
As reported in the abstract
Observational data: associations, not effects.
Further findings
Mean
| Outcome | ≥56 years | 16-55 years | Δ (95% CI) | P value | |
|---|---|---|---|---|---|
| Mean TIR, users with optimal settings (Glucose Target 100 mg/dL; active insulin time 2 h) | 81.9% | 79.7% | 2.2 (1.5–2.9) | P < 0.0001 | |
| −2024Difference (linear scale) |
TIR and TBR70 over time in older users · 12 months
- In older users, TIR and TBR70 remained consistent over 12 months
Safety
TBR <70 mg/dL (TBR70), across all users
- Mean TBR70 in older users
- 1.5%
- Mean TBR70 in younger users
- 2.1%
- In older users, TIR and TBR70 remained consistent over 12 months
Original publication
MiniMed 780G system performance in older users with type 1 diabetes: Real‐world evidence and the case for stricter glycaemic targets. Diabetes Obes Metab. Published 4 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →